Gildeuretinol

Gildeuretinol is an investigational new drug being developed by for the treatment of retinal diseases, particularly Stargardt disease and geographic atrophy secondary to age-related macular degeneration. Stargardt disease is caused by a defect in the ABCA4 gene that clears toxic byproducts resulting from the dimerization of vitamin A. Gildeuretinol is new molecular entity designed to reduce the dimerization of vitamin A in the eye without affecting the visual cycle.
Gildeuretinol has received breakthrough therapy, orphan drug and Pediatric Rare Disease designations from the U.S. Food and Drug Administration.